Key Points
- Insider sale: Director Harlan Robins sold 10,000 shares of Adaptive Biotechnologies at an average price of $14.85 (total $148,500) under a pre‑arranged Rule 10b5‑1 plan, trimming his stake by 0.66% to 1,512,058 shares (≈$22.45M).
- Mixed earnings: Adaptive reported Q results that beat estimates (EPS -$0.09 vs -$0.19; revenue $71.68M vs $59.38M), with revenue up 51% year‑over‑year, but the company remains unprofitable with a negative net margin (~21.5%) and negative ROE.
- Market and sentiment: Shares fell ~4.6% (opened $12.79) amid a market cap of ~$1.97B, while analyst coverage is mixed but averages a "Moderate Buy" with a mean price target of $18.25 and institutional ownership at ~99.17% (notably Invesco increased its stake significantly).
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the firm's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $14.85, for a total transaction of $148,500.00. Following the transaction, the insider owned 1,512,058 shares of the company's stock, valued at approximately $22,454,061.30. This represents a 0.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adaptive Biotechnologies Stock Down 4.6%
Shares of ADPT opened at $12.79 on Friday. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -31.97 and a beta of 2.29. Adaptive Biotechnologies Corporation has a 12 month low of $6.77 and a 12 month high of $20.76. The company has a 50-day moving average price of $14.95 and a two-hundred day moving average price of $15.95.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to analysts' expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company's revenue for the quarter was up 51.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.23) earnings per share. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. raised its stake in shares of Adaptive Biotechnologies by 50.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 7,577 shares of the company's stock valued at $123,000 after acquiring an additional 2,550 shares during the last quarter. Corient Private Wealth LLC raised its position in Adaptive Biotechnologies by 3.4% in the 4th quarter. Corient Private Wealth LLC now owns 71,908 shares of the company's stock worth $1,168,000 after purchasing an additional 2,347 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies in the 4th quarter worth approximately $28,000. T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies in the 4th quarter worth approximately $51,000. Finally, Invesco Ltd. raised its position in Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company's stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the last quarter. Institutional investors own 99.17% of the company's stock.
Analyst Upgrades and Downgrades
ADPT has been the subject of a number of analyst reports. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a "buy" rating in a research note on Monday, January 26th. JPMorgan Chase & Co. lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of "Moderate Buy" and an average price target of $18.25.
Get Our Latest Stock Report on ADPT
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
